AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 121 min read$PTCT

Pauwels Eric sold $1.6M of PTCT

Pauwels Eric (CHIEF BUSINESS OFFICER) sold 21,277 shares of PTC THERAPEUTICS, INC. (PTCT) at $75.00 ($1.60M total) across 2 trades on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pauwels Eric
Published Jun 12, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTCT
Neutral
high confidence
Mentioned
$PTCT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTCTNeutralLow
01

Why it matters

Provides a fresh, primary-source datapoint on insider activity (open-market sale) by a senior officer, but with reduced interpretive power due to a pre-arranged 10b5-1 plan.

02

Market read

Traders may log the insider sale as a sentiment datapoint, but it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The filing does not indicate why shares were sold (taxes, diversification, planned liquidity), and the sale price matches the stated $75 execution, limiting inference about timing vs market moves.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-12; sale executed 2026-06-10

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for PTC Therapeutics.

Company-level read

Ticker impact

$PTCTNeutralHigh confidence
Context

PTCT insider Form 4 shows Chief Business Officer Eric Pauwels sold 21,277 shares in open-market transactions at $75/share.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted.

Evidence & confidence

The disclosure is a Form 4 insider sale (not a buy), but it explicitly cites a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal read-through to biotech/therapeutics sector; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal risk/valuation concerns; traders may still watch for follow-on selling or other negative disclosures.

Key entities

  • issuer
    PTC THERAPEUTICS, INC.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Pauwels Eric

    Chief Business Officer who sold 21,277 shares across two trades.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTCT insider trading history →

Related articles

AUG 27
$PTCTMedAI 8/10

Broader Sephience PKU Data Could Be A Game Changer For PTC Therapeutics (PTCT)

PTC Therapeutics (PTCT) presented new data on its PKU therapy Sephience at the 2026 SSIEM Symposium, showing benefits in lowering phenylalanine levels and diet liberalization across a broad PKU population. The data suggest Sephience could be relevant for a wider spectrum of PKU severity. PTC raised its full-year revenue guidance to US$1.18 billion to US$1.28 billion following stronger Q2 2026 results. Analysts have varying opinions on the company's future revenue and earnings, with some predicti

simplywall.st3 min
AUG 24
$PTCTMedAI 8/10

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics (NASDAQ: PTCT) announced new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile for PKU patients. Data include significant blood Phe reductions and benefits across patient subgroups. Sephience is approved in the U.S., EU, Japan, and other regions for PKU treatment.

morningstar.com2 min
AUG 24
$PTCTMedAI 8/10

PTC presents Sephience data at metabolic disorders symposium

PTC Therapeutics (PTCT) presented data on Sephience at a metabolic disorders symposium. Clinical trials and real-world data showed significant reductions in blood phenylalanine levels and dietary liberalization in PKU patients. Sephience is approved in the U.S., EU, and Japan. The drug carries warnings about bleeding risk and hypophenylalaninemia. PKU affects about 58,000 people globally.

investing.com2 min
AUG 24
$PTCTMedAI 8/10

PTC Wins Sangamo's Fabry Gene Therapy in Bankruptcy Auction

PTC Therapeutics won a bankruptcy auction for Sangamo Therapeutics' Fabry disease gene therapy, ST-920, paying $111M upfront and up to $100M in milestones. PTC outbid Astellas and TerSera. The deal requires court and regulatory approval. ST-920 showed positive clinical data, supporting an accelerated FDA approval pathway. Eli Lilly also acquired other Sangamo assets for $50M.

cgtlive.com3 min
AUG 13
$PTCTMedAI 9/10

PTC Expands Rare Disease Portfolio With ST-920 Acquisition

PTC Therapeutics (PTCT) agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million upfront plus milestones. PTC cites Phase 1/2 STAAR data and plans an accelerated approval BLA submission, with CMC due Q4 2026 and a 2027 launch. Close expected in Q3 2026.

rttnews.com4 min